About SR One
SR One is a venture capital firm founded in 1985. It is primarily based out of Redwood City, United States. As of Sep 2026, SR One is an active investor, having invested in 153 companies, with 8 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Post IPO round of Korsana Overall, SR One portfolio has seen 28 IPOs and 57 acquisitions including key companies like Amgen, Scynexis and Progyny. A lot of funds co-invest with SR One, with names like Novo Holdings sharing a substantial percentage of its portfolio. SR One has team of 17 people including 2 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 6 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
SR One's List of Top Investments
SR One has a portfolio of 153 companies. Their most notable investments are in TP Therapeutics and Nimbus Therapeutics.Their portfolio spans across United States, United Kingdom, Switzerland and 11 more locations. They have invested in Life Sciences, High Tech, HealthTech and 9 other sectors, across stages such as Series A, Series B and 6 more. Here is the list of top investments by SR One:1. Amgen
Developer of pharmaceutical products for treating multiple diseases. It manufactures and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology, and inflammation. In 2022, the company recorded annual revenues of $26.32B and a net profit of $6.55B.
Key facts about Amgen
- Founded Year: 1980
- Location: Thousand Oaks (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Employee Count: 39,308 as on Aug 31, 2026
- Investors: Digital Pharma Lab, Amgen Business Development and 11 Others
- Latest Funding Round: Post IPO, Mar 12, 2012, $*****
- Highlight: Public
2. Scynexis
Developing glucan synthase inhibitors for the treatment of fungal infections. The company's lead candidate is SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections. SCY-078 acts as a glucan synthase inhibitor against a broad range of Candida and Aspergillus species.
Key facts about Scynexis
- Founded Year: 1999
- Location: Jersey City (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $62.7M
- Employee Count: 49 as on Aug 31, 2026
- Investors: Foresite Capital, Decheng Capital and 14 Others
- Latest Funding Round: Post IPO, Apr 09, 2020, $*****
- Highlight: Public
3. Progyny
Provider of women’s health, fertility, family building benefits, and insurance. The company offers end-to-end benefits designed to be flexible and equitable, allowing members access to care and support. Programs include preconception, fertility, adoption, surrogacy, pregnancy, postpartum, return-to-work, parent and child well-being, menopause, and midlife support. The company provides access to a network of women’s health providers.
Key facts about Progyny
- Founded Year: 2008
- Location: New York City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $67.4M
- Employee Count: 947 as on Aug 31, 2026
- Investors: HTIF, Union Grove Venture Partners and 6 Others
- Latest Funding Round: Series B, May 02, 2017, $*****
- Highlight: Public
Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.
Key facts about Spero Therapeutics
- Founded Year: 2013
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $115M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: Atlas Venture, Lundbeck Foundation and 16 Others
- Latest Funding Round: Post IPO, Nov 14, 2022, $*****
- Highlight: Public
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.
Key facts about Nimbus Therapeutics
- Founded Year: 2009
- Location: Cambridge (United States)
- Stage: Series F
- Total Funding till date: $637M
- Employee Count: 102 as on Aug 31, 2026
- Investors: Access Industries, Bain Capital Life Sciences and 20 Others
- Latest Funding Round: Series F, Sep 06, 2023, $*****
- Highlight: Editors' Pick
SR One's Year-on-Year Investment Trends
SR One has invested in 153 companies over the last 34 years, with an average of 5 new investments annually in the last 10 years. In 2025, it made 11 investments, while as of Sep 2026, it has made 9 investments in this year. Its most recent first time investment was in Korsana and most recent follow-on round was in Crystalystx.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 5 | 4 | 9 |
2025 | 7 | 4 | 11 |
2024 | 7 | 3 | 10 |
2023 | 2 | 4 | 6 |
2022 | 4 | 4 | 8 |
2021 | 4 | 4 | 8 |
2020 | 6 | 4 | 10 |
2019 | 3 | 0 | 3 |
2018 | 2 | 6 | 8 |
2017 | 5 | 7 | 12 |
SR One's Investments by Stage
SR One has made 47 investments in Series A stage with an average round size of $51.5M, 38 investments in Series B stage with an average round size of $34.1M and 17 investments in Series C stage with an average round size of $82.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 47 |
Series B | 38 |
Series C | 17 |
Series D | 10 |
Seed | 4 |
Others | 5 |
Note: We have considered here, only first round of investments
SR One's Investments by Sector
SR One has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Enterprise Applications and HealthTech. Notably, it has invested in 127 Tech companies, 110 Enterprise (B2B) companies, 30 Software companies and at least 15 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 107 |
High Tech | 18 |
Sustainability Tech | 12 |
Enterprise Applications | 10 |
HealthTech | 10 |
Others | 15 |
Note: We have considered here, only first round of investments
SR One's Investments by Geography
SR One has made most investments in United States (86), followed by United Kingdom where it has made 17 investments.Country | No. of Investments |
|---|---|
United States | 86 |
United Kingdom | 17 |
Switzerland | 4 |
Israel | 3 |
Canada | 2 |
Others | 9 |
Note: We have considered here, only first round of investments
SR One's recent investments
SR One has made 9 investments in 2026 so far. Korsana and Crystalystx are the latest among them.Here are the most recent investments by SR One:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 10, 2026 | United States | Post IPO | 4007 | [+15] | |
Jul 22, 2026 | United States | Series B | 9544 | [+19] | |
Jul 07, 2026 | United States | Series D | 9032 | [+13] | |
May 04, 2026 | Switzerland | Series B | 2193 | [+11] | |
Mar 24, 2026 | United Kingdom | Series A | 5267 |
IPOs and Publicly Listed companies in SR One's Portfolio
28 of SR One's portfolio companies have become public. Odyssey got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $849M and Avalyn Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $753M.Here are SR One's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 08, 2026 | Dec 08, 2021 | Series A | 2838 | |
Apr 30, 2026 | Sep 27, 2023 | Series C | 2382 | |
Feb 04, 2026 | Oct 14, 2025 | Series C | 4216 | |
Sep 13, 2024 | May 03, 2024 | Series C | 9441 | |
Sep 03, 2024 | - | - | 6965 |
Acquired companies in SR One's Portfolio
57 companies from SR One's portfolio have been acquired. The most recent acquisition was Kartos Therapeutics in Jun 2026 by Ipsen for $*****.Here are SR One's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 29, 2026 | - | - | 4352 | |
Feb 23, 2026 | Oct 03, 2019 | Series B | 6020 | |
Oct 24, 2025 | Jul 17, 2024 | Series A | 7143 | |
Oct 01, 2025 | Aug 08, 2024 | Series C | 3891 | |
Aug 07, 2025 | Dec 31, 2001 | Series A | 8262 |
Team profile of SR One
SR One has a team of 17 members including 2 Partners, 1 Venture Partner and 2 Principals located in United States and United Kingdom. SR One's team sits on the board of 1 company.Here is a list of top team members in SR One:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Mateo | - | - | |
Partner | San Francisco | - | ||
Venture Partner | United States | - | - | |
Principal | London | - | - | |
Principal | San Francisco | - | - |
Co-investors of SR One
Over the past 34 years, 773 investors have co-invested in SR One's portfolio companies. This includes funds and angels.
- Invested before SR One: HHS, Atlas Venture and 196 others have invested in rounds before SR One. There are 6 companies where HHS has invested before SR One and 5 companies where Atlas Venture has invested before SR One.
- Top Co-investors of SR One: 301 investors entered a company along with SR One. These include investors like Novo Holdings (11 companies).
- Invested after SR One: A total of 274 investors have invested in SR One's portfolio after their investments. Top Investors include RA Capital Management (8 companies), Orbimed (7 companies) and Citadel (6 companies).
Recent News related to SR One
•
Immutrin Raises $87 Million Series A for Antibody Therapy DevelopmentGlobeNewswire•Mar 24, 2026•Frazier Life Sciences, Cambridge Innovation Capital, University of Cambridge, F-Prime Capital and 4 others
•
•
CORXEL Announces $287 Million Series D1 Financing for Cardiometabolic PipelineBenzinga•Jan 22, 2026•One Capital Management, RA Capital Management, RTW Investments, CORXEL and 11 others
•
AirNexis Therapeutics Raises $200M in Series A FundingFinSMEs•Jan 12, 2026•Frazier Life Sciences, Enavate Sciences, Orbimed, Goldman Sachs and 7 others
•
Poplar Therapeutics Secures $50M Series A for Anti-IgE Therapy DevelopmentPulse 2.0•Jan 09, 2026•Vida Ventures, SR One, ALDEN POPLAR CREEK REHAB AND HEALTH CARE CENTER, INC., Poplar Therapeutics and 2 others
•
Addition Therapeutics Announces $100 Million Funding for Genomic MedicineBenzinga•Dec 17, 2025•Abingworth, Addition Therapeutics, SR One, Pivotal Life Sciences and 3 others
•
Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Menintelligence360•Nov 12, 2025•Suvretta Capital Management, VeraDermics, Invus, Marshall Wace and 18 others
•
•
Mission Therapeutics Secures $13.3M to Advance Parkinson's Candidate MTX325 Through Clinical TrialsPR Newswire•Oct 15, 2025•Mission Therapeutics, IP Group, Sofinnova Partners, Roche and 3 others
•
Novo-Backed Crystalys Debuts With $205M to Tackle GoutBioSpace•Sep 30, 2025•Crystalystx, AN Venture Partners, Catalys Pacific, KB Investment and 9 others
